Company Update (NYSE:BMY): In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1

[Business Wire] – Bristol-Myers Squibb Company and Pfizer Inc. today announced the results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes . . . → Read More: Company Update (NYSE:BMY): In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 Similar Articles: Stock Update (NYSE:BMY): U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Gains 6% on Promising Cancer Treatment, Upgrade